Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

[1]  R. Pommier,et al.  Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. , 2014, Surgery.

[2]  A. Bellizzi,et al.  A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. , 2014, Surgery.

[3]  M. Cuggia,et al.  High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation , 2014, The Journal of Nuclear Medicine.

[4]  A. Bellizzi,et al.  Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors , 2014, Clinical & Experimental Metastasis.

[5]  Donghong Wang,et al.  Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. , 2014, The Journal of surgical research.

[6]  P. Ruszniewski,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[7]  J. Chabot,et al.  Nonfunctional pancreatic neuroendocrine tumors. , 2014, The Surgical clinics of North America.

[8]  A. Bellizzi,et al.  Elevated pancreatic polypeptide levels in pancreatic neuroendocrine tumors and diabetes mellitus: causation or association? , 2014, Pancreas.

[9]  T. O'Dorisio,et al.  Pancreastatin Predicts Survival in Neuroendocrine Tumors , 2014, Annals of Surgical Oncology.

[10]  D. Yu,et al.  Midgut neuroendocrine tumors: imaging assessment for surgical resection. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[11]  K. Shah,et al.  Surgery for metastatic neuroendocrine tumors with occult primaries. , 2013, The Journal of surgical research.

[12]  G. Stalla,et al.  Somatostatin receptors: From signaling to clinical practice , 2013, Frontiers in Neuroendocrinology.

[13]  C. Divino,et al.  Serum pancreastatin: The next predictive neuroendocrine tumor marker , 2013, Journal of surgical oncology.

[14]  M. Falconi,et al.  Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI , 2013, La radiologia medica.

[15]  P. Capelli,et al.  Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour , 2013, European Radiology.

[16]  I. Drozdov,et al.  The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood , 2013, PloS one.

[17]  D. Metz,et al.  Consensus guidelines for the management and treatment of neuroendocrine tumors. , 2013, Pancreas.

[18]  J. Buscombe,et al.  Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature , 2013, Nuclear medicine communications.

[19]  Y. Menda,et al.  The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors , 2013, Annals of Surgical Oncology.

[20]  A. Sundin.  Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. , 2012, Best practice & research. Clinical gastroenterology.

[21]  G. Mamikunian,et al.  Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms. , 2012, Surgery.

[22]  Matthew J. Oborski,et al.  Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors , 2012, Molecular imaging and radionuclide therapy.

[23]  S. Dry,et al.  Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier , 2012, Clinical Cancer Research.

[24]  G. Mamikunian,et al.  A Prospective Evaluation of the Effect of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans , 2012, Pancreas.

[25]  V. Ambrosini,et al.  68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Pat Zanzonico,et al.  Principles of Nuclear Medicine Imaging: Planar, SPECT, PET, Multi-modality, and Autoradiography Systems , 2012, Radiation research.

[27]  T. Gress,et al.  ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas , 2011, Neuroendocrinology.

[28]  M. Falconi,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors , 2011, Neuroendocrinology.

[29]  H. Sasano,et al.  ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms , 2011, Neuroendocrinology.

[30]  Abhishek Kumar,et al.  Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. , 2011, AJR. American journal of roentgenology.

[31]  M. Makary,et al.  EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. , 2011, Gastrointestinal endoscopy.

[32]  R. Baum,et al.  Standard imaging techniques for neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.

[33]  N. Alazraki,et al.  The role of single-photon emission computed tomography and SPECT/computed tomography in oncologic imaging. , 2011, Seminars in oncology.

[34]  I. Modlin,et al.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors , 2011, Langenbeck's Archives of Surgery.

[35]  O. Rorstad,et al.  Role of imaging in the preoperative staging of small bowel neuroendocrine tumors. , 2010, Journal of the American College of Surgeons.

[36]  Manal M. Hassan,et al.  The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum , 2010, Pancreas.

[37]  D. Coppola,et al.  The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems , 2010, Pancreas.

[38]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[39]  M. Choti,et al.  Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis , 2010, Annals of Surgical Oncology.

[40]  D. Salvo,et al.  Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors: A Single-Centre Retrospective Study , 2010, Clinical nuclear medicine.

[41]  D. Shutt,et al.  Tomography Imaging Targets in Ileal and Pancreatic Neuroendocrine Tumors , 2010 .

[42]  A. Al-nahhas,et al.  Functional assessment in the multimodality imaging of pancreatic neuro-endocrine tumours. , 2010, Minerva endocrinologica.

[43]  David Cella,et al.  Health-Related Quality of Life of Patients With Neuroendocrine Tumor Compared to the United States General Population , 2010 .

[44]  L. Yip,et al.  Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients , 2010, Journal of Gastrointestinal Surgery.

[45]  A. Vinik,et al.  Biochemical Testing for Neuroendocrine Tumors , 2009, Pancreas.

[46]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  C. Hoeffel,et al.  Detection of Hepatic Metastases from Carcinoid Tumor: Prospective Evaluation of Contrast-Enhanced Ultrasonography , 2009, Digestive Diseases and Sciences.

[48]  E. Krenning,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide , 2009, Neuroendocrinology.

[49]  M. Rothmund,et al.  Neuroendocrine tumors of the pancreas. , 2009, The oncologist.

[50]  P. Malfertheiner,et al.  Detection of Neuroendocrine Tumors of the Small Bowel by Double Balloon Enteroscopy , 2009, Digestive Diseases and Sciences.

[51]  T. McDade,et al.  Pancreatic neuroendocrine tumors , 2009, Cancer.

[52]  B. Skogseid,et al.  Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors , 2009, Neuroendocrinology.

[53]  C. Ko,et al.  Small Bowel Cancer in the United States: Changes in Epidemiology, Treatment, and Survival Over the Last 20 Years , 2009, Annals of surgery.

[54]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[55]  A. M. Shapiro,et al.  The impact of preoperative endoscopic ultrasound on the surgical management of pancreatic neuroendocrine tumours. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[56]  M. Spampatti,et al.  Neuroendocrine tumors of the gastro-entero-pancreatic system. , 2008, World journal of gastroenterology.

[57]  K. Klose,et al.  Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[58]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  I. Drozdov,et al.  From Leningrad to London: The Saga of Kulchitsky and the Legacy of the Enterochromaffin Cell , 2008, Neuroendocrinology.

[60]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  W. Schima,et al.  MDCT of small bowel tumours , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

[62]  C. Ko,et al.  Clinicopathologic Features and Treatment Trends of Pancreatic Neuroendocrine Tumors: Analysis of 9,821 Patients , 2007, Journal of Gastrointestinal Surgery.

[63]  Mark Borden,et al.  Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. , 2007, Annual review of biomedical engineering.

[64]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  D. A. Anthoney,et al.  Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples , 2007, Annals of clinical biochemistry.

[66]  T. Yeatman,et al.  Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors , 2007, Annals of Surgical Oncology.

[67]  R. Jensen,et al.  Gastrinoma (Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[68]  B. Diggs,et al.  Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. , 2006, Surgery.

[69]  E. Kuipers,et al.  Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. , 2006, Gastrointestinal endoscopy.

[70]  C. Patterson,et al.  Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours , 2006, Gut.

[71]  D. O'Connor,et al.  Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. , 2005, The Journal of clinical endocrinology and metabolism.

[72]  J. Reubi.  Somatostatin and Other Peptide Receptors as Tools for Tumor Diagnosis and Treatment , 2004, Neuroendocrinology.

[73]  M. Bonnen,et al.  Adenocarcinoma of the small bowel , 2004, Cancer.

[74]  R. Wahl,et al.  Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS , 2004, Abdominal Imaging.

[75]  G. Lucignani,et al.  Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours , 2004, Nuclear medicine communications.

[76]  M. Bergström,et al.  PET in the Diagnosis of Neuroendocrine Tumors , 2004, Annals of the New York Academy of Sciences.

[77]  A. Engel,et al.  SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours , 2003, Clinical endocrinology.

[78]  M. Terzolo,et al.  Proinsulin-secreting neuroendocrine tumor of the pancreas , 2003, Journal of endocrinological investigation.

[79]  K. Calhoun,et al.  Serum peptide profiles in patients with carcinoid tumors. , 2003, American journal of surgery.

[80]  M. Stridsberg,et al.  A comparison between three commercial kits for chromogranin A measurements. , 2003, The Journal of endocrinology.

[81]  E. D. de Vries,et al.  Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. , 2000, Clinical chemistry.

[82]  Michelle A. Anderson,et al.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.

[83]  L. Karnell,et al.  The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. , 1999, Cancer.

[84]  E. Seregni,et al.  Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors , 1999, Cancer.

[85]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[86]  M. Gershon.  Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel , 1999, Alimentary pharmacology & therapeutics.

[87]  S. Fanti,et al.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours , 1998, European Journal of Nuclear Medicine.

[88]  D. Rubello,et al.  Neuroendocrine Tumor Imaging: Can 18F-Fluorodeoxyglucose Positron Emission Tomography Detect Tumors with Poor Prognosis and Aggressive Behavior? , 1998, World Journal of Surgery.

[89]  J. Crothers,et al.  Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. , 1998, QJM : monthly journal of the Association of Physicians.

[90]  E. Krenning,et al.  Somatostatin‐receptor Scintigraphy in Gastroenteropancreatic Tumors , 1994, Annals of the New York Academy of Sciences.

[91]  L. Kvols,et al.  Distribution of somatostatin receptors in normal and tumor tissue. , 1990, Metabolism: clinical and experimental.

[92]  E. Wilander,et al.  Malignant Carcinoid Tumors An Analysis of 103 Patients with Regard to Tumor Localization, Hormone Production, and Survival , 1987, Annals of surgery.

[93]  M. Wolfe,et al.  Secretin injection test in the diagnosis of gastrinoma. , 1980, Gastroenterology.

[94]  A. Andrew.  Further evidence that enterochromaffin cells are not derived from the neural crest. , 1974, Journal of embryology and experimental morphology.

[95]  A. Pearse.  Common cytochemical properties of cells producing polypeptide hormones, with particular reference to calcitonin and the thyroid C cells , 1966, Veterinary Record.

[96]  A. Morrison,et al.  Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. , 1958, The American journal of medicine.

[97]  M. K. Alexander,et al.  ISLET-CELL TUMOUR OF THE PANCREAS WITH PEPTIC ULCERATION, DIARRHŒA, AND HYPOKALÆMIA , 1957 .

[98]  J. Berlin,et al.  Neuroendocrine tumors, version 1.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[99]  S. Dry,et al.  A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors , 2014, Modern Pathology.

[100]  D. Sahani,et al.  Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. , 2013, Radiology.

[101]  V. Ambrosini,et al.  Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[102]  R. Bale,et al.  Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007 .

[103]  T. de Baère,et al.  Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Éó,et al.  Octreotide , 2000 .

[105]  E. D. de Vries,et al.  Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. , 1994, Clinical chemistry.

[106]  A. Vinik,et al.  Endocrine tumors of the gastroenteropancreatic axis , 1984 .

[107]  B. Stabile,et al.  The gastrinoma triangle: operative implications. , 1984, American journal of surgery.